VIFOR-PHARMA
21.12.2021 07:02:12 CET | Business Wire | Press release
Regulatory News:
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
Vifor Pharma today announced positive findings in the completed phase-IIIb DIAMOND trial of Veltassa® in heart failure patients with either manifest hyperkalemia or with a history of hyperkalemia while treated with renin-angiotensin aldosterone system inhibitor (RAASi) therapy. Veltassa® demonstrated a statistically significant difference versus placebo for the primary endpoint to serum potassium levels in a high risk population.
85% of the more than 1,000 patients with either high risk of hyperkalemia or active hyperkalemia were able to be optimized to guideline recommended, life-saving RAASi treatment, including mineralocorticoid receptor antagonists, with Veltassa® during the run-in phase of the study. This shows that the gap between guideline recommendations and real-world practice regarding the use of RAASi can be addressed with Veltassa® . Veltassa® was generally well tolerated and without unexpected safety findings. Vifor Pharma expects the key trial results to be presented at a major cardiology conference in H1 2022.
“We are delighted and very encouraged about the positive read-out from the DIAMOND trial for the heart failure patient community,” said Dr. Klaus Henning Jensen, Chief Medical Officer of Vifor Pharma. “RAASi therapy saves lives and delays disease progression, but unfortunately many patients with heart failure are insufficiently treated due to risk of hyperkalemia. Hyperkalemia is a serious condition associated with life-threatening consequences. These data support an effective management of chronic hyperkalemia in heart failure patients on optimal RAASi therapy with Veltassa® . We look forward to presenting the detailed data to the scientific community in the first half of 2022.”
“This trial makes a significant contribution to the growing body of evidence showing the importance to use Veltassa® to enable RAASi and ensures optimal treatment in a high-risk population”, commented Prof. Javed Butler, Principal Investigator for the DIAMOND study. “The totality of evidence from the trials with patiromer suggests the treatment to control serum potassium and preventing hyperkalemia in heart failure patients aiding longer term optimal medical therapy.”
Vifor Pharma continues to support several data generation programs with the ongoing phase-IV PLATINUM study and the CARE-HK in HF global registry to drive evidence-based care using Veltassa® in chronic kidney disease and heart failure patients.
About the DIAMOND trial
This global, multicenter, double-blind, placebo controlled study was designed to evaluate the potential role of Veltassa®
in enabling patients with, or at high risk of, hyperkalemia to remain on RAASi therapy. On recommendation of the independent study Executive Committee and due to COVID-19 impact on recruitment, the primary endpoint has been changed in June 2021 to investigate the role of Veltassa®
in controlling serum potassium, preventing hyperkalemia and maintain RAASi use in heart failure patients.
About Vifor Pharma Group
Vifor Pharma Group is a global pharmaceuticals company. It aims to become the global leader in iron deficiency, nephrology and cardio-renal therapies. The company is a partner of choice for pharmaceuticals and innovative patient-focused solutions. Vifor Pharma Group strives to help patients around the world with severe and chronic diseases lead better, healthier lives. The company develops, manufactures and markets pharmaceutical products for precision patient care. Vifor Pharma Group holds a leading position in all its core business activities and consists of the following companies: Vifor Pharma and Vifor Fresenius Medical Care Renal Pharma (a joint company with Fresenius Medical Care). Vifor Pharma Group is headquartered in Switzerland, and listed on the Swiss Stock Exchange (SIX Swiss Exchange, VIFN, ISIN: CH0364749348).
For more information, please visit viforpharma.com
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211220005646/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
MBRYONICS Announces Further Expansion in Its Customer Base and Manufacturing Facilities to Meet Rapidly Growing Demand20.4.2026 09:00:00 CEST | Press release
MBRYONICS has been expanding its partner and customer ecosystem and has recently been selected by the European Space Agency (ESA) for in-orbit demonstration activities in a team led by Kepler Communications. The €18.6M award is under Element 3 of the High-throughput Optical Network (HydRON) program, a project under ESA’s Optical and Quantum Communications – ScyLight program, within the agency’s Advanced Research in Telecommunications Systems (ARTES). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260420035633/en/ MBRYONICS was chosen to be part of this mission following its successful contribution to HydRON Element 2, where the company delivered optical testbed facilities to provide system reliability. In collaboration with Kepler Communications for Element 3, MBRYONICS optical terminal (StarCom), and its ground station test bed, have been selected to demonstrate full interoperability with other optical terminal providers du
Echodyne Named as Radar System for Trust Automation’s $490M Air Force Counter-UAS Engineering Contract20.4.2026 09:00:00 CEST | Press release
EchoShield® radar integrated into Small-Unmanned Air Defense System (SUADS) to deliver on $490M Air Force IDIQ Echodyne, the radar platform company, today announces its inclusion as a primary radar system within Trust Automation’s Small-Unmanned Air Defense System (SUADS) Counter-UAS platform, to be delivered to the U.S. Air Force under a $490M IDIQ contract announced in August 2025. Rapidly Deployable Small-Unmanned Air Defense System (RD-SUADS), Fixed Site Small-Unmanned Air Defense System (FS-SUADS), and Expeditionary Small-Unmanned Air Defense System (EX-SUADS) platforms adhere to the Sensor Open Systems Architecture (SOSA) standard with EchoShield radars being the first fully integrated SOSA solution in the platform. The RD-SUADS platform is a self-contained, self-powered C-UAS system fitted to standard pallet sizes for easy transport via military aircraft, while the FS-SUADS is for deployment at permanent military installations and can be integrated as a group or standalone for d
QAD | Redzone Brings the Future of Agentic AI in Manufacturing to Hannover Messe 202620.4.2026 08:00:00 CEST | Press release
The company will showcase how agentic AI is driving real-time execution so manufacturers can operate faster, adapt continuously and deliver measurable business outcomes. QAD | Redzone, the company redefining manufacturing and supply chains through intelligent, adaptive solutions, will showcase its AI-powered manufacturing platform that empowers the entire workforce, from the top floor to the shop floor, at Hannover Messe 2026, taking place April 20-24 in Hannover, Germany. At this year’s event, QAD | Redzone will show how manufacturing is entering a new phase where AI turns traditional systems of record into systems of action, empowering manufacturers to move from fragmented systems and delayed decisions to real-time, coordinated execution across the business. “Manufacturers don’t have a data problem, they have an execution problem,” said Sanjay Brahmawar, CEO at QAD | Redzone. “With agentic AI, we can create unprecedented visibility, but the value will only be realized when that intel
SymphonyAI Launches Eight AI Applications Purpose-Built for Energy Asset Reliability and Operational Performance20.4.2026 07:09:00 CEST | Press release
Eight AI applications engineered for asset reliability, operational performance, and emissions obligations SymphonyAI, a global leader in Vertical AI platforms, today announced eight new industrial AI applications purpose-built for energy operators, marking the most targeted expansion of IRIS Foundry into the energy sector to date. Unlike generic asset management software, these applications are engineered around the specific failure modes, process dynamics, and regulatory obligations of energy and resources operations — compressor surge, heat exchanger fouling, pipeline integrity degradation, refinery unit yield loss, and the growing compliance burden of EU methane regulation and emissions reporting. By combining SymphonyAI’s deep industrial ontology with IRIS Foundry’s ability to unify IT, OT, and IoT data from historians, SCADA systems, inspection databases, and enterprise platforms into a single governed intelligence layer, the new suite delivers causal AI at the point where energy
Petronor and H2SITE Partner to Pioneer High-Purity Hydrogen Production in Refining Through Advanced Membrane Technology20.4.2026 07:00:00 CEST | Press release
H2SITE, a technology company specialised in advanced hydrogen production and separation solutions, has signed a strategic agreement with Petronor, a leading refinery and key industrial player in the energy sector with a clear commitment to achieving net-zero emissions, to deploy its high-efficiency hydrogen separation technology at Petronor’s refinery. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260419792308/en/ The partnership sets the stage for the joint development of a pioneering First-of-a-Kind (FOAK) unit, integrating H2SITE’s proprietary membrane technology into the Steam Methane Reforming (SMR) process in refineries to improve overall plant efficiency, enhance CO₂ capture opportunities, and ultimately strengthen operational performance and industrial competitiveness. Petronor’s engineering and operations teams are joining forces with H2SITE’s technical experts, leveraging decades of refinery expertise, industrial
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom